US Markets

Zydus Cadila's COVID-19 vaccine candidate found safe in early-stage human trial

Credit: REUTERS/DADO RUVIC

India's Zydus Cadila said on Wednesday its COVID-19 vaccine candidate was found to be safe and well-tolerated in an early-stage human trial.

BENGALURU, Aug 5 (Reuters) - India's Zydus Cadila CADI.NS said on Wednesday its COVID-19 vaccine candidate was found to be safe and well-tolerated in an early-stage human trial.

The company will now start a mid-stage trial of the vaccine candidate, ZyCoV-D, in over 1,000 healthy adult volunteers from Thursday to test its effectiveness, it said in a regulatory filing.

Zydus plans to complete late-stage trials for ZyCoV-D by February or March and could produce up to 100 million doses a year initially, the company's chairman told Reuters last month.

The safety of the vaccine candidate in volunteers enrolled in the early-stage trial, who were administered doses since July 15, was endorsed by an independent data safety monitoring board.

Zydus is also among the several Indian generic drugmakers that have licensing agreements with U.S.-based Gilead Sciences GILD.O to produce remdesivir, the antiviral that has been approved in the country as an emergency treatment to fight the coronavirus outbreak.

India reported a daily jump of more than 50,000 coronavirus infections for the seventh straight day on Wednesday. Total cases now stand at 1.91 million, the third biggest, after the United States and Brazil.

(Reporting by Anuron Kumar Mitra in Bengaluru; Editing by Saumyadeb Chakrabarty)

((AnuronKumar.Mitra@thomsonreuters.com; +91 99863 58469;))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

GILD

Latest Markets Videos

Reuters

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

Learn More